JP2017501695A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501695A5
JP2017501695A5 JP2016537434A JP2016537434A JP2017501695A5 JP 2017501695 A5 JP2017501695 A5 JP 2017501695A5 JP 2016537434 A JP2016537434 A JP 2016537434A JP 2016537434 A JP2016537434 A JP 2016537434A JP 2017501695 A5 JP2017501695 A5 JP 2017501695A5
Authority
JP
Japan
Prior art keywords
group
adenovirus according
adenovirus
transgene
cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016537434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501695A (ja
JP6804133B2 (ja
Filing date
Publication date
Priority claimed from GBGB1322851.5A external-priority patent/GB201322851D0/en
Priority claimed from PCT/EP2014/072919 external-priority patent/WO2015059303A1/en
Application filed filed Critical
Publication of JP2017501695A publication Critical patent/JP2017501695A/ja
Publication of JP2017501695A5 publication Critical patent/JP2017501695A5/ja
Application granted granted Critical
Publication of JP6804133B2 publication Critical patent/JP6804133B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016537434A 2013-12-23 2014-12-23 アデノウイルスおよび対応するプラスミドの作製方法 Active JP6804133B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1322851.5 2013-12-23
GBGB1322851.5A GB201322851D0 (en) 2013-12-23 2013-12-23 Method
EPPCT/EP2014/072919 2014-10-24
PCT/EP2014/072919 WO2015059303A1 (en) 2013-10-25 2014-10-24 Oncolytic adenoviruses armed with heterologous genes
PCT/EP2014/079162 WO2015097220A1 (en) 2013-12-23 2014-12-23 A method of making adenovirus and corresponding plasmids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020197533A Division JP7104994B2 (ja) 2013-12-23 2020-11-27 アデノウイルスおよび対応するプラスミドの作製方法

Publications (3)

Publication Number Publication Date
JP2017501695A JP2017501695A (ja) 2017-01-19
JP2017501695A5 true JP2017501695A5 (cg-RX-API-DMAC7.html) 2018-02-08
JP6804133B2 JP6804133B2 (ja) 2020-12-23

Family

ID=50114629

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016537434A Active JP6804133B2 (ja) 2013-12-23 2014-12-23 アデノウイルスおよび対応するプラスミドの作製方法
JP2020197533A Active JP7104994B2 (ja) 2013-12-23 2020-11-27 アデノウイルスおよび対応するプラスミドの作製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020197533A Active JP7104994B2 (ja) 2013-12-23 2020-11-27 アデノウイルスおよび対応するプラスミドの作製方法

Country Status (10)

Country Link
US (1) US10472648B2 (cg-RX-API-DMAC7.html)
JP (2) JP6804133B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160102024A (cg-RX-API-DMAC7.html)
CN (1) CN106062199B (cg-RX-API-DMAC7.html)
AU (1) AU2014372562B2 (cg-RX-API-DMAC7.html)
CA (1) CA2934015A1 (cg-RX-API-DMAC7.html)
GB (1) GB201322851D0 (cg-RX-API-DMAC7.html)
IL (1) IL246235B (cg-RX-API-DMAC7.html)
SG (1) SG11201604801WA (cg-RX-API-DMAC7.html)
WO (1) WO2015097220A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO3021859T3 (cg-RX-API-DMAC7.html) 2013-10-25 2018-04-28
EA037611B1 (ru) 2015-04-30 2021-04-21 Псайоксус Терапьютикс Лимитед Онколитический аденовирус, кодирующий белок b7
WO2017103291A1 (en) * 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Virus encoding an anti-tcr-complex antibody or fragment
SG11201901716TA (en) 2016-08-29 2019-03-28 Psioxus Therapeutics Ltd Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
US20200017862A1 (en) * 2017-03-07 2020-01-16 University Of North Carolina Charlotte Systems and methods for single-strand break signaling and repair in a cell-free system
US11253608B2 (en) 2017-05-26 2022-02-22 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
JP7394628B2 (ja) * 2017-06-01 2023-12-08 アカミス バイオ リミテッド 腫瘍溶解性ウイルスおよび方法
EA202090700A1 (ru) * 2017-10-16 2020-10-21 Глаксосмитклайн Байолоджикалс Са Компетентные по репликации аденовирусные векторы
CN108424932B (zh) * 2018-03-13 2021-01-05 北京多赢时代转化医学研究院 重组溶瘤腺病毒、用于制备该重组溶瘤腺病毒的重组溶瘤腺病毒载体及其构建方法和应用
GB201814141D0 (en) * 2018-08-30 2018-10-17 Univ Oxford Innovation Ltd Method and compositions for producing a virus
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CN113186151A (zh) * 2021-03-03 2021-07-30 郑州大学 一种提高腺病毒产毒能力的单克隆细胞、细胞库及制备方法
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015823A1 (en) 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
CN1221666C (zh) * 2003-09-02 2005-10-05 广东省人民医院 腺病毒穿梭质粒及其构建方法
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
DE602005025340D1 (de) * 2004-05-26 2011-01-27 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
US20090208924A1 (en) * 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
BRPI0615400A2 (pt) * 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
WO2012024351A2 (en) 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method
CA2812093A1 (en) 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
CN105407902A (zh) 2013-03-05 2016-03-16 贝勒医学院 溶瘤病毒
AU2014352749A1 (en) 2013-11-22 2016-06-09 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
EA037611B1 (ru) 2015-04-30 2021-04-21 Псайоксус Терапьютикс Лимитед Онколитический аденовирус, кодирующий белок b7

Similar Documents

Publication Publication Date Title
JP2017501695A5 (cg-RX-API-DMAC7.html)
JP2018139586A5 (cg-RX-API-DMAC7.html)
De Haan et al. Viral gene delivery vectors: the next generation medicines for immune-related diseases
EA201791971A1 (ru) Онколитический аденовирус, кодирующий белок b7
JP2015096070A5 (cg-RX-API-DMAC7.html)
JP2017538401A5 (cg-RX-API-DMAC7.html)
JP2015506704A5 (cg-RX-API-DMAC7.html)
JP2016514956A5 (cg-RX-API-DMAC7.html)
JP2019523008A5 (cg-RX-API-DMAC7.html)
JP2015533841A5 (cg-RX-API-DMAC7.html)
Badovinac et al. TRAIL deficiency delays, but does not prevent, erosion in the quality of “helpless” memory CD8 T cells
RU2019107976A (ru) Композиция вакцины
FI3294325T3 (fi) Car-muokattujen t-solujen vaikutuksen parantaminen nukleeinihapporokotuksella
JP2014503206A5 (cg-RX-API-DMAC7.html)
EP4286407A3 (en) Anti-mutated kras t cell receptors
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
JP2016527891A5 (cg-RX-API-DMAC7.html)
JP2017537622A5 (cg-RX-API-DMAC7.html)
RU2017111298A (ru) Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2
JP2014524445A5 (cg-RX-API-DMAC7.html)
JP2016531927A5 (cg-RX-API-DMAC7.html)
EP4043021A3 (en) Oncolytic tumor viruses and methods of use
CL2020002954A1 (es) Célula modificada por ingeniería genética, que expresa un receptor exógeno que se une a un antígeno diana y a ccl21 exógena, y que es capaz de expresar una proteína de unión a il-7r o a il-7 exógena; y usos relacionados
JP2019508044A5 (cg-RX-API-DMAC7.html)
JP2015506961A5 (cg-RX-API-DMAC7.html)